Rationale for anti-OX40 cancer immunotherapy
European Journal of Cancer2015Vol. 52, pp. 50–66
Citations Over TimeTop 1% of 2015 papers
Sandrine Aspeslagh, Sophie Postel‐Vinay, Sylvie Rusakiewicz, Jean‐Charles Soria, Laurence Zitvogel, Aurélien Marabelle
Related Papers
- → Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma(2020)52 cited
- → Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer(2016)34 cited
- → A progressive T cell exhaustion program mapped across tissues in patients with lung cancer on immune checkpoint blockade(2023)4 cited
- → Tumor organoid-originated biomarkers predict immune response to PD-1 blockade(2021)7 cited
- → Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer(2014)